If we see less ‘startup’ costs against the balance sheet and more sales into their owned brands, margins will significantly improve and stable operational costs will strengthen their capital growth.
It will be interesting to see what it’s pharmaceutical partnerships will do for them in the next set of figures too.
AU8 Price at posting:
24.0¢ Sentiment: Hold Disclosure: Held